Phytoestrogenic Herbs in Menopause: A 2026 Systematic Review of Safety and Efficacy

Dr. Meera Iyer — Mon, 04 May 2026 09:00:00 +0000

Herbs described as “phytoestrogenic” are often promoted as natural alternatives to menopausal hormone therapy, but the term can mislead. A plant constituent may bind an estrogen receptor in a laboratory assay without reproducing estradiol’s clinical effects, and powders, decoctions, fermented medicines, and concentrated extracts may differ greatly. Among the Ayurvedic drugs discussed for menopause, Shatavari has the most direct human evidence, although it remains short-term and product-specific. Yashtimadhu has limited hot-flash evidence but important glycyrrhizin-related risks. Ashoka and Vidarikanda have verified Ayurvedic uses but no convincing standalone evidence for menopausal vasomotor symptoms.

Phytoestrogens: Mechanism and Limits

Phytoestrogens are plant-derived compounds capable of interacting with estrogen-related pathways. Human estrogen receptors include ERalpha and ERbeta. In competition-binding experiments, Kuiper and colleagues found that several phytoestrogens, including genistein, coumestrol, apigenin, naringenin, and kaempferol, bound more strongly to ERbeta than ERalpha, although most had much lower affinity than estradiol.

Preferential ERbeta binding is not proof of benefit or safety. Effects depend on concentration, metabolism, tissue, receptor balance, and whether a compound acts as an agonist, partial agonist, or antagonist. It is therefore inaccurate to present ERalpha as simply harmful and ERbeta as uniformly protective.

A 2006 meta-analysis by Trock and colleagues pooled 18 epidemiological studies of soy exposure and breast-cancer risk: 12 case-control studies and six cohort or nested case-control studies. High versus low soy intake showed a modest inverse association overall (OR 0.86, 95% CI 0.75-0.99), while the Asian-country subgroup was not statistically significant (OR 0.89, 95% CI 0.71-1.12). The authors noted heterogeneous exposure assessment, possible confounding, and no clear dose-response. These dietary-soy findings cannot be transferred directly to concentrated Ayurvedic extracts or used as proof of safety during cancer treatment.

Isoflavones include genistein, daidzein, and puerarin.
Licorice flavonoids include glabridin and liquiritigenin.
Steroidal saponins include shatavarins from Asparagus racemosus.

Shatavari (Asparagus racemosus)

The Ayurvedic Pharmacopoeia of India identifies Shatavari as the tuberous root of Asparagus racemosus Willd. Its profile is madhura and tikta rasa, snigdha and guru guna, shita virya, and madhura vipaka. Listed actions include vrishya, balya, medhya, rasayana, Pittahara, Vatahara, stanyakara, and hridya. These Ayurvedic classifications should not be translated automatically into claims that Shatavari replaces estrogen or “balances hormones.”

The API lists sugar, glycosides, saponin, and sitosterol among its constituents and gives 3-6 g as the dose of the crude drug. It names preparations including Shatavari Ghrita and Shatavari Kalpa. Shatavarins are steroidal saponins used to characterize modern extracts, but their concentration varies. A crude-root dose cannot be converted directly into an extract dose without the extraction ratio and chemical specification.

Clinical Evidence

A 2024 double-blind, multicentre, randomized placebo-controlled trial enrolled 70 women and tested a proprietary Shatavari root extract at 250 mg twice daily for 60 days. The authors reported greater improvement in several menopausal symptoms and quality-of-life measures than with placebo, with no significant adverse events recorded. The sample and follow-up were limited, and the result applies only to the tested product.

A 2025 randomized, double-blind, placebo-controlled study randomized 80 perimenopausal women to a standardized Shatavari root extract at 300 mg once daily or placebo for eight weeks; 73 completed the study per protocol. The investigators reported greater improvement in Menopause Rating Scale and hot-flash measures, without reported adverse events or short-term deterioration in measured liver and kidney variables.

The 2025 trial was single-centre, short, and excluded women with breast or cervical carcinoma. Ixoreal Biomed supplied the study products, while the article reported no specific research grant and no author conflicts. Calling it simply “manufacturer-sponsored” therefore exceeds the published disclosure. Neither trial establishes long-term, endometrial, cardiovascular, comparative, or cancer-specific safety.

Dosing and Formulation

There is no verified universal Shatavari-extract range of 300 mg-2 g daily. The API dose concerns crude root, whereas trials used defined proprietary extracts. Products with different extraction ratios or marker profiles are not milligram-for-milligram equivalents.

Preparation	Verified Dose	Meaning
Dried root	3-6 g	API crude-drug dose
2024 trial extract	250 mg twice daily for 60 days	Product-specific evidence
2025 trial extract	300 mg once daily for eight weeks	Product-specific evidence

Yashtimadhu (Glycyrrhiza glabra)

The API identifies Yashti or Yashtimadhu as the dried, unpeeled stolon and root of Glycyrrhiza glabra Linn. Its profile is madhura rasa, guru and snigdha guna, shita virya, and madhura vipaka. Listed actions include Vatapittajit, raktaprasadana, balya, varnya, vrishya, and cakshushya. The API gives 2-4 g of powdered drug and lists uses including kasa, svarabheda, kshaya, vrana, and Vatarakta; menopause is not a specific pharmacopoeial indication.

Licorice contains glycyrrhizin and multiple flavonoids. In a human breast-cancer cell model, glabridin showed estrogen-receptor-dependent growth-promoting activity at lower concentrations and receptor-independent antiproliferative activity at higher concentrations. Liquiritigenin showed relative ERbeta selectivity experimentally. These studies suggest mechanisms but do not establish cancer safety or clinical benefit from whole licorice root.

Hot Flashes and Safety

A double-blind placebo-controlled trial by Nahidi and colleagues enrolled 90 postmenopausal women. Participants received three capsules daily, each containing 330 mg of the tested licorice preparation or placebo, for eight weeks, followed by four weeks of observation. The investigators reported reduced hot-flash frequency and severity followed by recurrence after treatment ended. This modest trial of one preparation does not establish a universal dose.

Repeated or excessive glycyrrhizin exposure can cause sodium and water retention, potassium loss, hypertension, oedema, muscle weakness, and cardiac-rhythm disturbances. Risk is greater in susceptible people, including those with hypertension or heart or kidney conditions, and licorice can interact with medicines. Deglycyrrhizinated licorice was not tested in the hot-flash trial, and informal “cyclic dosing” has not been validated as a safeguard. The original recommendation of 1-2 g of standardized extract daily is therefore unsupported.

Ashoka (Saraca asoca)

The API identifies Ashoka as the dried stem bark of Saraca asoca. Its profile is kashaya and tikta rasa, laghu and ruksha guna, shita virya, and katu vipaka. Listed actions include grahi, varnya, hridya, shothahara, and vishaghna. The API names asrigdara among its uses, lists Ashokarishta and Ashokaghrita as formulations, and gives 20-30 g of bark for decoction.

Asrigdara is associated with abnormal or excessive uterine bleeding, supporting Ashoka’s authentic place in Ayurvedic gynecology but not proving benefit for hot flashes. A genuine 2023 Journal of Ethnopharmacology review documents the plant’s history, chemistry, and experimental pharmacology, but does not provide robust randomized menopause evidence. Ashokarishta is multi-ingredient, so its effects cannot be assigned to Ashoka alone. New heavy, prolonged, or postmenopausal bleeding requires medical evaluation.

Vidarikanda (Pueraria tuberosa)

The API identifies Vidari or Vidarikanda as the dried tuberous root of Pueraria tuberosa DC. Its profile is madhura rasa, snigdha and guru guna, shita virya, and madhura vipaka. Listed actions include Vatahara, Pittahara, stanyada, mutrala, jivaniya, rasayana, brimhana, varnya, and balya. The API gives 3-6 g as the powdered-drug dose.

Pueraria tuberosa is not interchangeable with Pueraria lobata or Pueraria mirifica. Modern reviews report puerarin, daidzein, and genistein in studied P. tuberosa material, so the claim that puerarin occurs only in P. lobata is incorrect. The available review is dominated by laboratory and animal research and does not establish relief of menopausal hot flashes in controlled human trials. Vidarikanda’s verified nourishing and restorative actions should not be upgraded into a clinically proven phytoestrogen claim.

Hormone-Sensitive Conditions and Monitoring

Women with a personal history of estrogen-receptor-positive breast cancer, endometrial cancer, ovarian cancer, atypical endometrial hyperplasia, or another hormone-sensitive condition require particular caution. The cited Shatavari trials were not designed to determine cancer recurrence, long-term endometrial safety, or compatibility with oncology treatment, and the 2025 study excluded women with breast or cervical carcinoma.

Absence of harm in short trials that excluded such patients is not evidence of safety for cancer survivors. Product-specific interactions with tamoxifen or aromatase inhibitors should not be asserted without clinical evidence, but the exact product should be reviewed with an oncologist. No evidence establishes routine pelvic ultrasound after exactly 12 months of herb use; evaluation should be individualized. Unexpected or postmenopausal bleeding warrants prompt medical assessment.

Evidence Quality and Practical Use

Shatavari has more than one randomized menopause trial, but evidence remains preliminary because products, doses, populations, and outcomes differ and follow-up is short. Yashtimadhu has one modest hot-flash trial and a clear glycyrrhizin-related safety limitation. Ashoka and Vidarikanda have verified Ayurvedic roles, not robust standalone menopause trials. Pharmacopoeial evidence documents identity, Ayurvedic properties, traditional uses, and crude-drug doses; a clinical trial evaluates one defined product for selected outcomes. These forms of evidence should not be conflated.

Use authenticated products with botanical identity, plant part, extraction details, and contaminant testing.
Match dose to preparation; API crude-drug doses and proprietary extract doses are not interchangeable.
Treat Shatavari evidence as promising, not conclusive, especially for long-term or cancer-related safety.
Avoid casual prolonged Yashtimadhu use and review blood pressure, kidney and cardiac history, electrolyte risk, and medicines.
Do not stop prescribed hormone or oncology treatment because of an herbal claim.

Standardized Shatavari extracts currently have the clearest direct evidence among the herbs reviewed, but the findings remain product-specific. Yashtimadhu may reduce hot flashes in some women, yet its safety limitations prevent a universal recommendation. Ashoka and Vidarikanda are genuine Ayurvedic medicines whose traditional roles should not be converted into unsupported menopause claims.

This article is educational and does not constitute medical advice. Menopausal symptoms, abnormal uterine bleeding, and decisions about hormone therapy or herbal treatment should be reviewed with a qualified healthcare provider. Ayurvedic medicines should be selected under the supervision of a trained Ayurvedic practitioner. Anyone with a personal history of hormone-sensitive cancer should consult an oncologist before using a phytoestrogenic supplement.

Phytoestrogens – Ayurved Healing